Goserelin Dosing Options Included in the National Comprehensive Cancer Network® (NCCN) Breast Cancer Guidelines
- Press Release
- |
- February 5, 2024
News & insights
Discover the latest from TerSera
Goserelin Included in the National Comprehensive Cancer Network® (NCCN) Head and Neck Cancer Guidelines
- Press Release
- |
- October 24, 2023
TerSera® Presents Patient-Reported Clinical and Productivity Outcomes Associated with Xermelo® (Telotristat Ethyl): Long-Term Registry Trial of Patients with Carcinoid Syndrome Diarrhea
- Press Release
- |
- November 9, 2021
TerSera® Announces Publication of Real-World Study on Xermelo® (Telotristat Ethyl) in Patients with Carcinoid Syndrome Diarrhea
- Press Release
- |
- October 27, 2021
TerSera® Presents Data on Cetirizine HCl Injection (QUZYTTIR®) in the Prevention of Hypersensitivity Infusion Reactions in Patients with Breast Cancer and Other Malignancies
- Press Release
- |
- March 5, 2021
TerSera® Announces Addition of Cetirizine as an Adjunctive Treatment to Interim CDC Guidelines for Managing Adverse Reactions After COVID-19 Vaccination
- Press Release
- |
- February 23, 2021
Lexicon Pharmaceuticals Enters Into Agreement with TerSera Therapeutics LLC for Xermelo
- Press Release
- |
- July 30, 2020
Jazz Pharmaceuticals Enters Into Agreement with TerSera Therapeutics LLC for Prialt
- Press Release
- |
- July 29, 2018
TESARO Enters Asset Purchase Agreement with TerSera® Therapeutics LLC for VARUBI® in the U.S. and Canada
- Press Release
- |
- June 28, 2018
AstraZeneca announced today that it has entered into an agreement with TerSera Therapeutics LLC (“TerSera”) for the commercial rights to Zoladex (goserelin acetate implant) in the US and Canada. This transaction is expected to close during Q1 of 2017.
- Press Release
- |
- February 20, 2017
